Rheumatology
Conference Coverage
Early axial spondyloarthritis diagnosis in referred patients remains stable in most
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis,...
Conference Coverage
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final...
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.
Feature
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...
Conference Coverage
Two biologics show no difference in axial spondyloarthritis radiographic progression over 2 years
This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at...
Conference Coverage
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
The risk for interstitial lung disease in patients with PsA during the first 5 years after starting a biologic or targeted synthetic DMARD was...
Conference Coverage
AxSpA remission on TNFi seen in half of patients with comorbid IBD
Those who had IBD for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axSpA remission...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
Conference Coverage
AxSpA effects may be more severe for Black patients
A higher percentage of Black patients had elevated erythrocyte sedimentation rate, C-reactive protein, and hip involvement in a small study. Black...
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.